- Home
- IH vs LPTX Comparison
IH vs LPTX Comparison
Compare IH & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IH
- LPTX
- Stock Information
- Founded
- IH 1996
- LPTX 2011
- Country
- IH China
- LPTX United States
- Employees
- IH N/A
- LPTX N/A
- Industry
- IH Other Consumer Services
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IH Real Estate
- LPTX Health Care
- Exchange
- IH Nasdaq
- LPTX Nasdaq
- Market Cap
- IH 123.1M
- LPTX 119.6M
- IPO Year
- IH 2020
- LPTX N/A
- Fundamental
- Price
- IH $2.35
- LPTX $0.38
- Analyst Decision
- IH
- LPTX Buy
- Analyst Count
- IH 0
- LPTX 2
- Target Price
- IH N/A
- LPTX $8.00
- AVG Volume (30 Days)
- IH 8.4K
- LPTX 317.5K
- Earning Date
- IH 07-01-2025
- LPTX 08-11-2025
- Dividend Yield
- IH 3.54%
- LPTX N/A
- EPS Growth
- IH N/A
- LPTX N/A
- EPS
- IH 0.25
- LPTX N/A
- Revenue
- IH $126,344,481.00
- LPTX N/A
- Revenue This Year
- IH $39.02
- LPTX N/A
- Revenue Next Year
- IH N/A
- LPTX N/A
- P/E Ratio
- IH $9.37
- LPTX N/A
- Revenue Growth
- IH N/A
- LPTX N/A
- 52 Week Low
- IH $1.47
- LPTX $0.22
- 52 Week High
- IH $3.18
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- IH 55.32
- LPTX 46.09
- Support Level
- IH $2.20
- LPTX $0.38
- Resistance Level
- IH $2.39
- LPTX $0.44
- Average True Range (ATR)
- IH 0.10
- LPTX 0.04
- MACD
- IH -0.01
- LPTX -0.00
- Stochastic Oscillator
- IH 91.90
- LPTX 22.52
About IH iHuman Inc.
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .